[go: up one dir, main page]

MX2013012284A - Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10). - Google Patents

Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).

Info

Publication number
MX2013012284A
MX2013012284A MX2013012284A MX2013012284A MX2013012284A MX 2013012284 A MX2013012284 A MX 2013012284A MX 2013012284 A MX2013012284 A MX 2013012284A MX 2013012284 A MX2013012284 A MX 2013012284A MX 2013012284 A MX2013012284 A MX 2013012284A
Authority
MX
Mexico
Prior art keywords
antibody
subject
ipio
dosage escalation
antibody dosage
Prior art date
Application number
MX2013012284A
Other languages
English (en)
Inventor
Allison Y Luo
Wendy L Trigona
Jinshan Shen
Li-An Xu
Yan Zhang
Bruce Stouffer
Haibin Chen
Catherine Brockus
Xiaolu Tao
Haichun Huang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2013012284A publication Critical patent/MX2013012284A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En ciertas modalidades, la presente invención proporciona un método de tratamiento de un trastorno relacionado a IP10 en un sujeto, que comprende: (a) administrarle al sujeto una dosis predeterminada de un anticuerpo anti-IP10; (b) detectar el nivel del anticuerpo anti-IP10 en una muestra del sujeto; y (c) si el nivel del anticuerpo anti-IP10 del paso (b) está por debajo de un nivel de exposición de umbral, se incrementa la dosis del anticuerpo anti-IP10 en el sujeto, tal que el trastorno relacionado a IP-10 en el sujeto, es tratado.
MX2013012284A 2011-04-29 2012-04-27 Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10). MX2013012284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480938P 2011-04-29 2011-04-29
PCT/US2012/035457 WO2012149320A1 (en) 2011-04-29 2012-04-27 Ip-10 antibody dosage escalation regimens

Publications (1)

Publication Number Publication Date
MX2013012284A true MX2013012284A (es) 2013-11-21

Family

ID=46026997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012284A MX2013012284A (es) 2011-04-29 2012-04-27 Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).

Country Status (9)

Country Link
US (2) US20140065164A1 (es)
EP (1) EP2702076A1 (es)
JP (1) JP2014516944A (es)
CN (1) CN103619880A (es)
BR (1) BR112013027867A2 (es)
CA (1) CA2834552A1 (es)
EA (1) EA201391582A1 (es)
MX (1) MX2013012284A (es)
WO (1) WO2012149320A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025328T2 (en) 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
MX2013012284A (es) 2011-04-29 2013-11-21 Bristol Myers Squibb Co Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
CA2946862A1 (en) * 2014-04-24 2015-10-29 Immusant, Inc. Use of interleukin-2 for diagnosis of celiac disease
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016081869A2 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
EP3067699A1 (en) * 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease
EP3355896A2 (en) * 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP7463272B2 (ja) 2017-09-07 2024-04-08 ブリストル－マイヤーズ スクイブ カンパニー キャピラリー電気泳動による純度の決定方法
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20240044918A1 (en) * 2020-12-22 2024-02-08 Radiometer Medical Aps Determining interference criticality based on analyte and cell-free hemoglobin concentrations
WO2024256527A1 (en) 2023-06-13 2024-12-19 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
CN117116471B (zh) * 2023-10-23 2024-01-23 四川大学华西医院 建立预测增殖或非增殖狼疮肾炎模型的方法及预测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (es) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
FR2046920B1 (es) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
AU8828601A (en) 2000-08-18 2002-03-04 Univ California Methods for treating demyelinating diseases
US20030166589A1 (en) 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis
AU2003294290A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
ATE501173T1 (de) 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
HUE025328T2 (en) 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
BRPI0509419A (pt) * 2004-04-16 2007-09-04 Genentech Inc método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio
DE602007013620D1 (de) * 2006-09-05 2011-05-12 Hvidovre Hospital Auf IP-10 basierende immunologische Überwachung
US7786268B2 (en) 2007-02-28 2010-08-31 Novimmune Sa Anti-IP-10 antibodies and methods of use thereof
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
MX2013012284A (es) 2011-04-29 2013-11-21 Bristol Myers Squibb Co Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).

Also Published As

Publication number Publication date
EA201391582A1 (ru) 2014-03-31
US20140127229A1 (en) 2014-05-08
US20140065164A1 (en) 2014-03-06
US9429581B2 (en) 2016-08-30
EP2702076A1 (en) 2014-03-05
CA2834552A1 (en) 2012-11-01
WO2012149320A1 (en) 2012-11-01
JP2014516944A (ja) 2014-07-17
BR112013027867A2 (pt) 2016-09-06
CN103619880A (zh) 2014-03-05

Similar Documents

Publication Publication Date Title
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA201792545A1 (ru) Способы и наборы для лечения депрессии
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
ZA202005388B (en) Methods of treating ulcerative colitis
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201790398A1 (ru) Способы лечения заболевания печени
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
MX346555B (es) Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201592203A1 (ru) Способы лечения таупатии
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EP2967900A4 (en) INTERMEDIATE CAGE AND METHOD FOR TREATING SWIVELS WITH AN INTERMEDIATE CAGE
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
EA201591943A1 (ru) Ингибиторы metap2 и способы лечения ожирения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal